复发性系统性轻链淀粉样变性——寻求更高标准。 - Suppr

Suppr

超能文献

Relapsed systemic light chain amyloidosis - in search of a higher bar.

作者信息

Baljevic Muhamed, Sengsayadeth Salyka

机构信息

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.

出版信息

Bone Marrow Transplant. 2024 Apr;59(4):441-443. doi: 10.1038/s41409-024-02203-8. Epub 2024 Jan 23.

DOI:10.1038/s41409-024-02203-8

PMID:38263391

Abstract

摘要

相似文献

Relapsed systemic light chain amyloidosis - in search of a higher bar.

Bone Marrow Transplant. 2024 Apr;59(4):441-443. doi: 10.1038/s41409-024-02203-8. Epub 2024 Jan 23.

How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis).

Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e826-e831. doi: 10.1016/j.clml.2020.06.017. Epub 2020 Jun 28.

[AL amyloidosis, from diagnosis to treatment].

Rev Prat. 2020 Dec;70(10):1137-1141.

A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.

Br J Haematol. 2022 Jul;198(2):328-332. doi: 10.1111/bjh.18216. Epub 2022 May 4.

How I Approach Light Chain Amyloidosis.

G Ital Nefrol. 2023 Oct 3;40(Suppl 81):2023-S81.

Treatment of immunoglobulin light chain (primary or AL) amyloidosis.

Oncology (Williston Park). 2011 Jun;25(7):620-6.

In search of the most effective therapy for light chain amyloidosis.

Amyloid. 2022 Mar;29(1):67-68. doi: 10.1080/13506129.2021.1974832. Epub 2021 Sep 12.

COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury.

Am J Med. 2022 Apr;135 Suppl 1:S49-S52. doi: 10.1016/j.amjmed.2022.01.005. Epub 2022 Jan 23.

Supportive Care for Patients with Systemic Light Chain Amyloidosis.

Hematol Oncol Clin North Am. 2020 Dec;34(6):1177-1191. doi: 10.1016/j.hoc.2020.08.007.

Systemic Light Chain Amyloidosis.

N Engl J Med. 2024 Jun 27;390(24):2295-2307. doi: 10.1056/NEJMra2304088.

本文引用的文献

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.

Blood Cancer J. 2021 Aug 4;11(8):139. doi: 10.1038/s41408-021-00529-w.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631.

Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.

Blood Cancer J. 2021 Feb 16;11(2):34. doi: 10.1038/s41408-021-00428-0.

Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.

Leuk Lymphoma. 2021 Apr;62(4):874-882. doi: 10.1080/10428194.2020.1849675. Epub 2020 Nov 20.

Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.

Hematol Oncol Clin North Am. 2020 Dec;34(6):1009-1026. doi: 10.1016/j.hoc.2020.08.001. Epub 2020 Sep 28.

Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis.

Am J Hematol. 2021 Jan;96(1):E20-E23. doi: 10.1002/ajh.26025. Epub 2020 Nov 5.

Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis.

Blood Cancer J. 2020 Sep 1;10(8):88. doi: 10.1038/s41408-020-00354-7.

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.

Blood. 2019 Dec 19;134(25):2271-2280. doi: 10.1182/blood.2019000834.

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.

Blood. 2015 Jul 30;126(5):612-5. doi: 10.1182/blood-2015-01-620302. Epub 2015 May 18.

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

J Clin Oncol. 2015 Apr 20;33(12):1371-8. doi: 10.1200/JCO.2014.57.4947. Epub 2015 Mar 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验